The EEA1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human 143B osteosarcoma cell line, featuring disruption of the EEA1 gene. This heterogeneous pool of cells offers a reliable loss-of-function model for investigating early endosome biology without the need for clonal isolation. The polyclonal format reduces clonal bias and is suitable for functional assays in membrane trafficking and cancer cell biology. The product provides stable gene disruption, enabling robust interrogation of EEA1-dependent processes.
The 143B cell line is a widely used model of osteosarcoma, originating from a 13-year-old female and displaying osteoblast-like characteristics. These cells are ideal for studying bone cancer pathogenesis, metastasis, and drug responses. Their active endocytic machinery makes them particularly relevant for examining how EEA1 loss affects receptor trafficking and autophagy within a tumor context.
EEA1 functions as a Rab5 effector and tethering factor essential for homotypic early endosome fusion. Recruited via Rab5-GTP and PI3P (generated by VPS34), EEA1 interacts with Rabaptin-5, Rabenosyn-5, and syntaxin-13 to drive SNARE-mediated membrane merger. Upstream, EGFR signaling modulates endosomal dynamics, while downstream EEA1 coordinates cargo sorting toward lysosomal degradation or recycling. Additionally, EEA1 participates in autophagy by facilitating endosome-autophagosome interactions, linking endosomal trafficking to cellular homeostasis.
In 143B osteosarcoma cells, EEA1 knockout provides a relevant system to dissect how endocytic pathway defects influence cancer phenotypes. Altered endosomal trafficking can dysregulate receptor tyrosine kinase signaling (e.g., EGFR) and nutrient uptake, impacting proliferation and survival. This polyclonal model captures population-level heterogeneity, enabling studies on drug sensitivity, metastasis, and therapeutic resistance. It is also valuable for assessing nanoparticle-based delivery and endosomal escape mechanisms.
Applications encompass transferrin uptake and EGFR degradation assays to quantify endocytosis and lysosomal targeting, immunofluorescence for endosome morphology, and co-immunoprecipitation to probe EEA1 interactomes. Autophagy flux analysis (LC3-II) and confocal tracking further elucidate EEA1’s role in trafficking. These tools make the cells ideal for cancer drug discovery and endocytosis research. For more information, please contact Ascent Research.
